DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscapes.
The report comprises Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Amyotrophic Lateral Sclerosis pipeline products.
Amyotrophic Lateral Sclerosis Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body.
Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, etc., are developing therapies for the treatment of Amyotrophic Lateral Sclerosis.
Emerging therapies such as Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.
Get an overview of pipeline landscape @ Amyotrophic Lateral Sclerosis Clinical Trials Analysis
Amyotrophic Lateral Sclerosis Pipeline Therapies along with Key Players:
Levosimendan: Orion Pharma
NurOwn: Brainstorm-Cell Therapeutics
Arimoclomol: Orphazyme
Ibudilast: MediciNova
Tofersen: Biogen
Verdiperstat: Biohaven Pharmaceutical
Pridopidine: Prilenia Therapeutics
AMX0035: Amylyx
Pegcetacoplan: Apellis Pharmaceuticals
Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight
Coverage: Global
Major Players: Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, and others.
Pipeline Therapies: Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, and others.
Table of Contents
1
Amyotrophic Lateral Sclerosis Report Introduction
2
Amyotrophic Lateral Sclerosis Executive Summary
3
4
Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment
5
Amyotrophic Lateral Sclerosis Pipeline Therapeutics
6
Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)
7
Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)
8
Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)
9
Amyotrophic Lateral Sclerosis Preclinical Stage Products
10
Amyotrophic Lateral Sclerosis Therapeutics Assessment
11
Amyotrophic Lateral Sclerosis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Amyotrophic Lateral Sclerosis Key Companies
14
Amyotrophic Lateral Sclerosis Key Products
15
Amyotrophic Lateral Sclerosis Unmet Needs
16
Amyotrophic Lateral Sclerosis Market Drivers and Barriers
17
Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion
18
Amyotrophic Lateral Sclerosis Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Amyotrophic Lateral Sclerosis Drugs Pipeline Report.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/